LOE Access Planning: Why Biosimilar Entry Can Reshape Class Economics Faster Than Manufacturers Expect
- Jul 2
- 4 min read
Want the downloadable brief? Get the full Signal 2 PDF and webinar replay resources from our Access Inflection resource page.
Loss of exclusivity is no longer just a product-specific milestone. In crowded categories, biosimilar and generic entry can quickly reshape payer expectations, comparator logic, formulary strategy, and the economics of an entire class.
During eMAX Health Systems’ webinar, The Access Inflection: When the 2025 Playbook Stops Working, a live panel of senior payer and market access leaders discussed five signals reshaping 2026 access planning for pharmaceutical and biotech teams.
The second signal: The Biosimilar Cliff Cascade.
For manufacturers, the risk is not only losing share after LOE. The bigger risk is underestimating how quickly payer logic can shift once lower-cost alternatives enter the category.
Biosimilar Management Is Getting Faster
As payers gain more experience managing biosimilar launches, the time between market entry and access disruption may continue to narrow.
One webinar panelist put it plainly:
“We’re not quite there with biosimilars, but we’re getting close.”
For traditional pharmacy benefit generics, some payers already move almost immediately once a lower-cost alternative is available in their systems. Biosimilars may not always move at that same speed yet, especially on the medical benefit, but payer processes are maturing.
Each new biosimilar launch creates more precedent, more operational confidence, and less tolerance for delayed response.
That matters for manufacturers because LOE planning can no longer be treated as a late-stage defensive exercise. By the time biosimilar competition enters the market, many payer assumptions may already be forming.
Clinical Hesitation Around Biosimilars Is Fading
The panel also made clear that payer comfort with biosimilars is increasing.
As that comfort grows, the access conversation shifts away from whether biosimilars are clinically acceptable and toward economics, contracting, switching strategy, and implementation.
One panelist noted:
“Once a biosimilar is approved and launched, we consider it to be the same as a brand.”
For manufacturers, this changes the burden of proof.
If a payer starts from a position of clinical comparability, a branded product needs a stronger case for why it should remain advantaged, preferred, or protected from step therapy when lower-cost alternatives are available.
That case may need to include more than historical brand familiarity or physician preference. It may require stronger evidence, clearer patient segmentation, contracting flexibility, and a payer-relevant explanation of why the brand still warrants access protection.
Differentiation Has to Be Payer-Relevant
In a biosimilar-driven environment, differentiation cannot live only in the clinical narrative. It has to matter to the payer.
When manufacturers claim best-in-class positioning, payers may ask a more basic question first: best by what measure?
As one medical director said during the discussion:
“We are looking for an MCID, a minimally clinically important difference.”
That distinction is important.
A product may be differentiated in a clinical presentation, but if that difference is not meaningful enough to affect payer coverage logic, it may not protect pricing, tiering, or formulary position.
For manufacturers, the evidence strategy needs to answer questions payers are likely to ask:
Is the difference clinically meaningful?
Is it economically justifiable?
Does it matter for the patients the payer covers?
Does it change utilization, outcomes, adherence, or total cost of care?
Is it strong enough to justify preferred access or protection from step therapy?
In other words, evidence must do more than show difference. It must show difference that payers recognize as meaningful.
Payer Engagement Needs to Begin Before the Cliff
LOE planning should not happen in a manufacturer-only echo chamber.
One panelist emphasized the need for earlier payer conversations:
“Start having the discussions with the payers, especially the big PBMs.”
Those conversations can help teams understand how payers may evaluate biosimilar entrants, what switching policies could look like, whether grandfathering is realistic, and which evidence or contracting scenarios may help defend value.
This is especially important because payer response is not always uniform. Depending on the category, benefit design, route of administration, site of care, contracting dynamics, and clinical context, payers may approach biosimilar management differently.
Manufacturers need to know where payers are likely to move quickly, where hesitation remains, and what evidence or contracting levers may influence access decisions before disruption begins.
What Manufacturers Should Pressure-Test Now
For teams preparing for 2026–2027 planning, the biosimilar cliff raises several important questions:
Are we treating LOE as a product event or a class-wide access reset?
Have we validated how payers may redefine the comparator set after biosimilar or generic entry?
Is our evidence clinically meaningful enough to defend access?
Are we generating real-world evidence early enough to protect brand value?
Have we started payer conversations before access disruption is expected?
Do our contracting and pricing scenarios reflect how quickly payers may move once biosimilars launch?
These questions matter because the biosimilar cliff is not a single moment. It is a cascade.
Once payers gain confidence, economic pressure can move across the class quickly.
Where MAVA® Fits
MAVA® helps pharmaceutical and biotech teams bring current payer and healthcare decision-maker insight into high-stakes access planning before market conditions shift.
For LOE and biosimilar planning, MAVA can help teams explore how payers may evaluate switching, step edits, comparator selection, evidence requirements, grandfathering, contracting scenarios, and formulary risk.
MAVA can help teams:
Validate how payers may respond to biosimilar or generic entry
Understand likely timing for formulary updates, step edits, and switching policies
Pressure-test whether clinical differentiation is meaningful enough to defend access
Explore grandfathering, parity coverage, and preferred positioning scenarios
Identify what real-world evidence may help protect brand value
Align Commercial, Medical, HEOR, Pricing, and Access teams around a more realistic LOE strategy
The goal is to move LOE planning from internal assumption to payer-informed strategy.
The Takeaway
Biosimilar and generic entry can change more than the economics of one product. It can reset how payers evaluate an entire class.
As payers become more experienced with biosimilar management, the window for manufacturers to react is narrowing. Teams that begin evidence planning, payer engagement, contracting scenario work, and access strategy earlier will be better positioned to defend value when the market shifts.
The 2026 playbook needs to account for faster payer action, stronger evidence requirements, and a more dynamic definition of value.
Now is the time to plan for the cascade before it starts.
